Search clinical trials for: HCV NS3 protease inhibitor

Total 68969 results

Athens Medical Society
Elpen Pharmaceutical Co. Inc.; OBCTCD24 Ltd

Recruiting

Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19

Covid19

Greece
Clinica Universidad de Navarra, Universidad de...
Centro de Investigación Médica Aplicada (CIMA)

Terminated

Phase I-II Vaccination of Autologous Dendritic Cells Transduced With Adenoviral Vector Encoding NS3 in Hepatitis C Encoding NS3 in Hepatitis C

Hepatitis C, Chronic
Beni-Suef University

Completed

Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4

Hepatitis C Virus Infection
Beni-Suef University

Completed

Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients

Chronic Hepatitis C Virus Infection

Egypt
Janssen-Cilag Ltd.

Completed

An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection (MAPPING)

Hepatitis C Virus

Brazil
Gilead Sciences

Terminated

GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype

Chronic Hepatitis C

United States, Australia, Canada, New Zealand
Bristol-Myers Squibb

Completed

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (D-LITE)

Hepatitis C

France, Germany, Italy, Japan, United States, Australia, Puerto Rico, Spain, New Zealand
Russian Academy of Medical Sciences

Completed

Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection

Liver Diseases | Virus Diseases | Hepatitis | Hepatitis C, Chronic

Russian Federation
Mayo Clinic

Recruiting

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Plasma Cell Myeloma

United States
Humanity and Health Research Centre
Beijing 302 Hospital; Nanfang Hospital of Southern Medical University

Recruiting

Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (SWITCH-1)

Chronic Hepatitis C Infection

China
M.D. Anderson Cancer Center

Completed

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic... and other conditions

United States
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants

Hepatitis C, Chronic

United States, Canada
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
Lisa Barrett
PEI Provincial Correction Centre

Active, not recruiting

Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment

Hepatitis C Virus
Benha University

Completed

Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters

Male Infertility | HCV

Egypt
Medical University of Graz

Completed

Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C

Chronic Hepatitis C

Austria
R-Pharm
Almedis; Scientific Center EFiS; ChromSystemsLab

Completed

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

Chronic Hepatitis c Genotype 1

Russian Federation
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

United States
Valme University Hospital
Hospital General Universitario Elche; Hospital del SAS de Jerez; Clinica Universidad... and other collaborators

Completed

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions (FPSMON201401)

Chronic Hepatitis C Infection

Spain
National Institute of Allergy and Infectious Diseases...

Completed

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

HIV Infections | Hepatitis C

United States
Humanity and Health Research Centre
Beijing 302 Hospital; Nanfang Hospital of Southern Medical University

Completed

DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (DASCO)

Chronic Hepatitis C Infection | Hepatitis B Reactivation | HBV Coinfection

China
AbbVie

Completed

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection (GIFT-II)

Hepatitis C Virus
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection (CERTAIN-1)

Hepatitis C Virus | Chronic Hepatitis C Virus
AbbVie

Completed

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I)

Hepatitis C Virus Infection | Chronic Hepatitis C | Human Immunodeficiency Virus Infection | Compensated Cirrhosis and Non-cirrhotics
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-III)

Compensated Cirrhosis | Chronic Hepatitis C Infection
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Chronic Hepatitis C
University of Colorado, Denver

Completed

Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers

Hepatitis C | HIV

United States
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO) (PROMO)

HCV Infections | Gastric Acid-related Disorders

Netherlands
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir (OPAL)

HIV Infections | HCV Infections

Netherlands
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

Chronic Hepatitis C
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

HCV

China
Beni-Suef University

Completed

ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants

Chronic Hepatitis C Virus Infection

Egypt
Beni-Suef University

Completed

Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients

Chronic Hepatitis C Virus Infection
Assiut University
Sohag University; South Valley University

Completed

Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease

End-stage Renal Disease | HCV Coinfection

Egypt
AbbVie

Completed

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II)

Hepatitis C Virus (HCV)
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Terminated

Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV/HCV Patients

HIV Infections

Spain
Ottawa Hospital Research Institute
AbbVie

Completed

Pilot HCV Direct Acting Antiviral Therapy and Metabolism (3D)

Hepatitis C

Canada
HaEmek Medical Center, Israel
AbbVie

Completed

Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B

HCV Coinfection

Israel
National Taiwan University Hospital

Completed

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

Hepatitis C | Viral Hepatitis C | Renal Disease

Taiwan
Assiut University
Sohag University; South Valley University

Completed

Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure

HCV Coinfection

Egypt
Kaohsiung Medical University Chung-Ho Memorial...
National Taiwan University Hospital; China Medical University Hospital; Chang... and other collaborators

Completed

Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV

Hepatitis C

Taiwan
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection

Chronic HCV Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

Chronic Hepatitis C Virus

United States
American Research Corporation
AbbVie

Completed

A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study (HEARTLAND)

Chronic Hepatitis C
AbbVie

Completed

ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

Chronic Hepatitis C Virus (HCV)
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Chronic Hepatitis C
Myeong Jun Song
Bristol-Myers Squibb; Korea University Guro Hospital; Severance Hospital; Eulji... and other collaborators

Completed

The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure

Hepatitis C

Korea, Republic of
AbbVie (prior sponsor, Abbott)

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

Chronic Hepatitis C Infection

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study

Chronic Hepatitis C
AbbVie

Completed

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection (GIFT I)

Chronic Hepatitis C Infection

3

Subscribe